After bicuspid aortic valve, ventricular septal defects (VSDs) are the most common congenital heart abnormalities. Of all congenital defects, around 20% are solitary lesions and another 10% are ...
Percutaneous closure of symptomatic ventricular septal defects in children can be achieved with off-label use of an occluder device. A research letter published online November 7, 2012, ahead of print ...
September 18, 2007 — The US Food and Drug Administration (FDA) has granted 510(k) clearance to 2 flexible digital endoscopes for diagnostic and therapeutic procedures and to a short-term catheter for ...
Perimembranous ventricular septal defects (VSDs) involving the membranous septum and the adjoining muscular septum are the most common form of congenital heart defect. Traditional surgical repair ...
A randomized trial has found low rates of procedural and long-term complications with three patent foramen ovale closure devices. Of note, a significantly lower rate of recurrent neurological events ...
NEW YORK (CBS 2) --Many mothers-to-be have ultrasounds during their pregnancy to catch their first glimpse of their baby in the womb. But imagine instead finding out your baby has a major heart defect ...
St. Joseph Hospital ’s Dr. Berdjis Performs Life-Saving Procedure First Time Done in Orange County , California Orange County, Calif. – Heart specialists at St. Joseph Hospital in Orange , Calif. have ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...
The FDA has given the green light to a tiny device made by Abbott that can fix a common heart defect in newborns, especially premature babies. The new device is tiny, even smaller than a pea. It can ...
St. Jude Medical (STJ) received an FDA safety alert for its Amplatzer ASO, a minimally-invasive implantable cardiac device used to treat atrial septal defect. The problem? In one to three of every ...
New data show zero device-related complications or atrial fibrillation, no recurrent stroke or TIA, with a cohort 40% larger than Gore and Amplatzer device studies FOUNTAIN VALLEY, Calif., Sept. 16, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback